Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 675 participants.

Also called NCT04083339

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 675 participants (planned count) (from the registry)
Sponsor
Applied Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT04083339
Other papers using this trial's data
  • Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial Cardiovascular diabetology, 2025-01-13 DOI, PubMed 39806375, PMC11730511 In the PMC Open Access subset under CC BY.
  • Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis Circulation. Heart failure, 2025-03 DOI, PubMed 39882614
  • Racial outcomes in patients with diabetic cardiomyopathy treated with an aldose reductase inhibitor: the ARISE-HF trial Open heart, 2026-07-31 DOI, PubMed 42538062, PMC13435914 In the PMC Open Access subset under CC BY-NC.
  • Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy Journal of the American College of Cardiology, 2024-07-09 DOI, PubMed 38597864
  • Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy Cardiovascular diabetology, 2024-08-02 DOI, PubMed 39095808, PMC11297788 In the PMC Open Access subset under CC BY-NC-ND.
  • Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study JACC. Heart failure, 2026-01 DOI, PubMed 40338768

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, Czechia, France, Germany, Hong Kong SAR China, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04083339. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-20 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Condition
Diabetic Cardiomyopathies
Intervention (Drug)
AT-001
Intervention (Drug)
Placebo
Lead sponsor
Applied Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04083339
Content hash
fafc79562770244b00d282f811ce896ed60ce61c3c2c842f6b088675d64592f4